Provided by Tiger Fintech (Singapore) Pte. Ltd.

vTv Therapeutics

18.26
-2.7300-13.01%
Post-market: 18.830.5700+3.12%16:05 EDT
Volume:120.23K
Turnover:2.28M
Market Cap:47.70M
PE:-2.61
High:21.60
Open:20.50
Low:17.46
Close:20.99
Loading ...

Alliance Global says clinical hold lift ‘de-risking’ event for vTv Therapeutics

TIPRANKS
·
18 Mar

BUZZ-U.S. STOCKS ON THE MOVE-Blackstone, PepsiCo, Blue Owl Capital

Reuters
·
18 Mar

vTv Therapeutics Soars 43% as FDA Lifts Clinical Hold on Diabetes Drug Trial

GuruFocus.com
·
18 Mar

VTv Therapeutics Shares Rise After FDA Lifts Hold on Diabetes Treatment

Dow Jones
·
17 Mar

BUZZ-vTv jumps after FDA lifts clinical hold on diabetes therapy

Reuters
·
17 Mar

vTv Therapeutics Shares up 22.6% as FDA Lifts Clinical Hold on Development of Co's Diabetes Therapy

THOMSON REUTERS
·
17 Mar

Vtv Therapeutics Says FDA Lifts Clinical Hold on Cadisegliatin Program for Diabetes; Shares Up Pre-Bell

MT Newswires Live
·
17 Mar

vTv Therapeutics says FDA has lifted clinical hold on cadisegliatin program

TIPRANKS
·
17 Mar

vTv Therapeutics Inc expected to post a loss of 87 cents a share - Earnings Preview

Reuters
·
07 Mar

vTv Therapeutics Inc - Steven Tuch to Resign as CFO Effective March 21

THOMSON REUTERS
·
28 Feb

vTv Therapeutics CFO Steven Tuch to Resign

TIPRANKS
·
28 Feb

We're Keeping An Eye On vTv Therapeutics' (NASDAQ:VTVT) Cash Burn Rate

Simply Wall St.
·
02 Feb

vTv Therapeutics initiated with a Buy at Alliance Global Partners

TIPRANKS
·
09 Dec 2024

Cantex Pharmaceuticals Receives FDA Orphan Drug Designation for Azeliragon for the Treatment of Brain Metastasis From Breast Cancer

THOMSON REUTERS
·
09 Dec 2024

CANTEX PHARMACEUTICALS RECEIVES FDA ORPHAN DRUG DESIGNATION FOR AZELIRAGON FOR THE TREATMENT OF BRAIN METASTASIS FROM BREAST CANCER

PR Newswire
·
09 Dec 2024

vTv Therapeutics Inc : Alliance Global Partners Initiates Coverage With Buy Rating; Target Price $35

THOMSON REUTERS
·
09 Dec 2024